| MeSH term | MeSH ID | Detail |
|---|---|---|
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Neuroblastoma | D009447 | 66 associated lipids |
| Leukemia-Lymphoma, Adult T-Cell | D015459 | 25 associated lipids |
| Parkinsonian Disorders | D020734 | 20 associated lipids |
Epothilone D
Epothilone d is a lipid of Polyketides (PK) class. Epothilone d is associated with abnormalities such as Tauopathies, Neutropenia, Neuropathy and Hematological Disease. The involved functions are known as Mutation, Apoptosis, Mitotic arrest, Cell Growth and Anabolism. Epothilone d often locates in Cytoskeleton, Axon, Cell Wall, Chromosomes and Spindle. The associated genes with epothilone D are SLC33A1 gene, Chromatin, GTF2I gene and HEXA gene.
Cross Reference
Introduction
To understand associated biological information of Epothilone D, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Epothilone D?
Epothilone D is suspected in Tauopathies, Neutropenia, Neuropathy, Hematological Disease and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Epothilone D
PubChem Associated disorders and diseases
What pathways are associated with Epothilone D
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Epothilone D?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Epothilone D?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Epothilone D?
There are no associated biomedical information in the current reference collection.
What genes are associated with Epothilone D?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Epothilone D?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with Epothilone D
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Kim TJ et al. | Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. | 2007 | Vascul. Pharmacol. | pmid:17706465 |
| Burris HA | Preclinical investigations with epothilones in breast cancer models. | 2008 | Semin. Oncol. | pmid:18410795 |
| Vahdat LT | Clinical studies with epothilones for the treatment of metastatic breast cancer. | 2008 | Semin. Oncol. | pmid:18410796 |
| Cartelli D et al. | Microtubule alterations occur early in experimental parkinsonism and the microtubule stabilizer epothilone D is neuroprotective. | 2013 | Sci Rep | pmid:23670541 |
| Altmann KH et al. | 4. The natural products epothilones A and B as lead structures for anticancer drug discovery: chemistry, biology, and SAR studies. | 2004 | Prog Med Chem | pmid:15003721 |
| Chou TC et al. | Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9689134 |
| Chou TC et al. | Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. | 1998 | Proc. Natl. Acad. Sci. U.S.A. | pmid:9861050 |
| Lichtner RB et al. | Subcellular distribution of epothilones in human tumor cells. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562452 |
| Chou TC et al. | The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11438750 |
| Xiong Y et al. | HDAC6 mutations rescue human tau-induced microtubule defects in Drosophila. | 2013 | Proc. Natl. Acad. Sci. U.S.A. | pmid:23487739 |
| Brunden KR et al. | The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. | 2011 | Pharmacol. Res. | pmid:21163349 |
| Chappell MD et al. | En route to a plant scale synthesis of the promising antitumor agent 12,13-desoxyepothilone B. | 2000 | Org. Lett. | pmid:10841497 |
| Stachel SJ et al. | On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB: a Mitsunobu inversion at C15 in pre-epothilone fragments. | 2000 | Org. Lett. | pmid:10841498 |
| Taylor RE and Chen Y | Total synthesis of epothilones B and D. | 2001 | Org. Lett. | pmid:11440584 |
| Frein JD et al. | New sources of chemical diversity inspired by biosynthesis: rational design of a potent epothilone analogue. | 2009 | Org. Lett. | pmid:19572566 |
| Gaich T and Mulzer J | Synthesis of epothilones via a silicon-tethered RCM reaction. | 2005 | Org. Lett. | pmid:15787494 |
| Chen QH et al. | Design, synthesis and biological evaluation of bridged epothilone D analogues. | 2008 | Org. Biomol. Chem. | pmid:19039362 |
| Penazzi L et al. | Aβ-mediated spine changes in the hippocampus are microtubule-dependent and can be reversed by a subnanomolar concentration of the microtubule-stabilizing agent epothilone D. | 2016 | Neuropharmacology | pmid:26772969 |
| Brizuela M et al. | The microtubule-stabilizing drug Epothilone D increases axonal sprouting following transection injury in vitro. | 2015 | Mol. Cell. Neurosci. | pmid:25684676 |
| Nakano M et al. | Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. | 2011 | Mol. Cell Proteomics | pmid:21859949 |
| Lee SH et al. | Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. | 2007 | Mol. Cancer Ther. | pmid:17938270 |
| Chappell MD et al. | Probing the SAR of dEpoB via chemical synthesis: a total synthesis evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B. | 2002 | J. Org. Chem. | pmid:12398496 |
| Rivkin A et al. | Total syntheses of [17]- and [18]dehydrodesoxyepothilones B via a concise ring-closing metathesis-based strategy: correlation of ring size with biological activity in the epothilone series. | 2002 | J. Org. Chem. | pmid:12398497 |
| Mulzer J et al. | Total syntheses of epothilones B and D. | 2000 | J. Org. Chem. | pmid:11076603 |
| Keck GE et al. | Total synthesis of epothilones B and D: stannane equivalents for beta-keto ester dianions. | 2008 | J. Org. Chem. | pmid:18991385 |
| Jung JC et al. | Total syntheses of epothilones B and d. | 2004 | J. Org. Chem. | pmid:15609966 |
| Wessjohann LA et al. | Total synthesis of epothilone D: the nerol/macroaldolization approach. | 2013 | J. Org. Chem. | pmid:24079664 |
| Brunden KR et al. | Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. | 2010 | J. Neurosci. | pmid:20943926 |
| Barten DM et al. | Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. | 2012 | J. Neurosci. | pmid:22623658 |
| Zhang B et al. | The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. | 2012 | J. Neurosci. | pmid:22423084 |
| Dietzmann A et al. | Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton. | 2003 | J. Neurooncol. | pmid:14686728 |
| Killinger BA and Moszczynska A | Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers. | 2016 | J. Neurochem. | pmid:26465779 |
| Fournet V et al. | Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice. | 2012 | J. Neurochem. | pmid:23013328 |
| Verrills NM et al. | Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. | 2006 | J. Natl. Cancer Inst. | pmid:17018783 |
| Hardt IH et al. | New natural epothilones from Sorangium cellulosum, strains So ce90/B2 and So ce90/D13: isolation, structure elucidation, and SAR studies. | 2001 | J. Nat. Prod. | pmid:11473410 |
| Arslanian RL et al. | A new cytotoxic epothilone from modified polyketide synthases heterologously expressed in Myxococcus xanthus. | 2002 | J. Nat. Prod. | pmid:12141877 |
| Arslanian RL et al. | Large-scale isolation and crystallization of epothilone D from Myxococcus xanthus cultures. | 2002 | J. Nat. Prod. | pmid:11975503 |
| Starks CM et al. | Isolation and characterization of new epothilone analogues from recombinant Myxococcus xanthus fermentations. | 2003 | J. Nat. Prod. | pmid:14575429 |
| Ye W et al. | A new approach for improving epothilone B yield in Sorangium cellulosum by the introduction of vgb epoF genes. | 2016 | J. Ind. Microbiol. Biotechnol. | pmid:26803504 |
| Hause G et al. | Epothilone D affects cell cycle and microtubular pattern in plant cells. | 2005 | J. Exp. Bot. | pmid:15967777 |
| Zhang C et al. | Simultaneous determination of epothilone D and its hydrolytic metabolite in human plasma by high performance liquid chromatography-tandem mass spectrometry for pharmacokinetic studies. | 2009 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:19775943 |
| Yuan L et al. | Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLC-MS/MS assay. | 2014 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:25151331 |
| Nagano S et al. | Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK. | 2003 | J. Biol. Chem. | pmid:12933799 |
| Tang L et al. | Generation of novel epothilone analogs with cytotoxic activity by biotransformation. | 2003 | J. Antibiot. | pmid:12670045 |
| White JD et al. | Total synthesis of epothilone B, epothilone D, and cis- and trans-9,10-dehydroepothilone D. | 2001 | J. Am. Chem. Soc. | pmid:11389619 |
| Jumaa M et al. | Kinetics and mechanism of degradation of epothilone-D: an experimental anticancer agent. | 2004 | J Pharm Sci | pmid:15459947 |
| Wang Z et al. | Determination of desoxyepothilone B in nude mice plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. | 2006 | J Pharm Biomed Anal | pmid:16616824 |
| Burrell RC et al. | Synthesis of stable isotope-labeled epothilone D using a degradation-reconstruction approach. | 2015 | J Labelled Comp Radiopharm | pmid:26158758 |
| Bergstralh DT et al. | A comparison of signaling activities induced by Taxol and desoxyepothilone B. | 2004 | J Chemother | pmid:15700849 |
| Monk JP et al. | A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors. | 2012 | Invest New Drugs | pmid:21826439 |